person · Reporting owner

Wysenski Nancy

Disclosed activity across 6 companies

Tapewire entity: 16754
SEC CIK: 0001294596

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alkermes plc.ALKS · Entity 2392	Director	July 07, 2023	July 11, 2023
CYTOKINETICS INCCYTK · Entity 3528	Director	July 15, 2026	July 16, 2026
TETRAPHASE PHARMACEUTICALS INCTTPH · Entity 147285	Director	June 10, 2019	June 11, 2019
VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875	EVP, Chief Commercial Officer	May 14, 2012	June 01, 2012

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alkermes plc.

Report date July 07, 2023 · Filed July 11, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	20,356	Ending reported balance After 2023-07-07 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-07-07 · Exercise / conversion · Acquired 5,957 · Balance 21,786 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2023-07-07 · Tax withholding · Disposed 1,430 · Balance 20,356
Restricted Stock Unit AwardSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-07-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-07-07 · Exercise / conversion · Disposed 5,957 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: This award is fully vested in accordance with its terms.
Ordinary SharesSEC Table I · non-derivative	IndirectThe Nancy J. Wysenski Revocable Trust	11,242	Reported balance Holding disclosure · report date 2023-07-07 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 11,242 F2: The reporting person is a trustee and a beneficiary of The Nancy J. Wysenski Revocable Trust, established on September 23, 2014 ("The Nancy J. Wysenski Revocable Trust").

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2: The reporting person is a trustee and a beneficiary of The Nancy J. Wysenski Revocable Trust, established on September 23, 2014 ("The Nancy J. Wysenski Revocable Trust").

F3: This award is fully vested in accordance with its terms.

CYTOKINETICS INC

Report date July 15, 2026 · Filed July 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	33,992	Reported balance After 2026-07-15 transaction · row 1 1 source row Row 1 · 2026-07-15 · Grant · Acquired 75 · Balance 33,992 F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

TETRAPHASE PHARMACEUTICALS INC

Report date June 10, 2019 · Filed June 11, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2029-06-09	Direct	16,500	Reported balance After 2019-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-10 · Grant · Acquired 16,500 · Balance 16,500 F1: Vests in equal quarterly installments over a one-year period measured from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Vests in equal quarterly installments over a one-year period measured from the date of grant.

VERTEX PHARMACEUTICALS INC / MA

Report date May 14, 2012 · Filed June 01, 2012 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	32,232	Last balance in matching sequence After 2012-05-14 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2012-05-14 · Sale · Disposed 179,628 · Balance 32,604 F1: Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan. F2: Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82). F3: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 2 · 2012-05-14 · Sale · Disposed 372 · Balance 32,232 F1: Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan.

Filing footnotes · ownership attribution and instrument terms

F1: Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan.

F2: Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82).

F3: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Dova Pharmaceuticals Inc.

Report date November 12, 2019 · Filed November 12, 2019

Section 16 reporting ended · disclosed 2019-11-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-11-12 transaction · row 1 1 source row Row 1 · 2019-11-12 · Disposition to issuer · Disposed 6,274 · Balance 0 F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.36 · Expires 2029-04-25	Direct	0	Reported balance After 2019-11-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.

F2: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.

Provention Bio, Inc.

Report date April 27, 2023 · Filed April 27, 2023

Section 16 reporting ended · disclosed 2023-04-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.16	Direct	Reported balance After 2023-04-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-04-27 · Disposition to issuer · Disposed 128,981 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $12.62	Direct	Reported balance After 2023-04-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-04-27 · Disposition to issuer · Disposed 22,200 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.80	Direct	Reported balance After 2023-04-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-04-27 · Disposition to issuer · Disposed 23,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.52	Direct	Reported balance After 2023-04-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-04-27 · Disposition to issuer · Disposed 33,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full.

F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 15, 2026 Filed Jul 16, 2026 20:35 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	75	$82.62	$6,196.50	Disclosure SEC source: 0001061983-26-000083 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,992 F1 · kind: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant. Read SEC document
May 27, 2026 Filed May 27, 2026 23:07 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	4,301	$0.00 Strike: $77.15	$0.00	Disclosure SEC source: 0001061983-26-000054 · form4.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,301 Underlying: Common Stock · 4,301 shares Expires 2036-05-26 Read SEC document
May 27, 2026 Filed May 27, 2026 23:07 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	2,851	$0.00	$0.00	Disclosure SEC source: 0001061983-26-000054 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,917 Read SEC document
April 15, 2026 Filed Apr 15, 2026 22:37 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	95	$65.37	$6,210.15	Disclosure SEC source: 0001061983-26-000042 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,066 F1 · kind: Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program. Shares are fully vested. Read SEC document
January 15, 2026 Filed Jan 16, 2026 21:22 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	98	$63.44	$6,217.12	Disclosure SEC source: 0001061983-26-000008 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,971 F1 · kind: Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of our Board of Directors. Read SEC document
October 15, 2025 Filed Oct 16, 2025 20:32 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	99	$62.80	$6,217.20	Disclosure SEC source: 0001061983-25-000010 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,873 F1 · kind: Director equity in lieu of cash retainer program. Read SEC document
July 15, 2025 Filed Jul 16, 2025 21:45 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	164	$38.01	$6,233.64	Disclosure SEC source: 0001127602-25-019292 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,774 F1 · kind: Director equity in lieu of cash retainer program. Read SEC document
May 14, 2025 Filed May 14, 2025 23:23 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	10,880	$0.00 Strike: $30.00	$0.00	Disclosure SEC source: 0001127602-25-014354 · form4.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,880 Underlying: Common Stock · 10,880 shares Expires 2035-05-13 F2 · kind: Comprised of stock options that will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier to occur of (x) the one-year anniversary of the date of the grant and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. Read SEC document
May 14, 2025 Filed May 14, 2025 23:23 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	7,333	$0.00	$0.00	Disclosure SEC source: 0001127602-25-014354 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,610 F1 · kind: Comprised of restricted stock units ("RSUs") that will vest in one installment on the earlier to occur of (x) the one-year anniversary of the grant date and (y) the date of the issuer's annual meeting of stockholders for the calendar year immediately subsequent to the grant date, subject to the director's continuous service as a member of the issuer's Board of Directors. RSUs convert to shares of common stock on a 1:1 basis upon vesting. Read SEC document
April 15, 2025 Filed Apr 16, 2025 20:02 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	162	$38.56	$6,246.72	Disclosure SEC source: 0001127602-25-012112 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,277 F1 · kind: Shares acquired pursuant to Director Stock in lieu of Cash Retainer Program. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:23 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	127	$48.93	$6,214.11	Disclosure SEC source: 0001127602-25-000761 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,115 F1 · kind: Director Stock in Lieu of Cash Retainer Program Read SEC document
October 01, 2024 Filed Oct 3, 2024 21:24 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	118	$52.60	$6,206.80	Disclosure SEC source: 0001127602-24-025193 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,988 F1 · kind: Stock award in lieu of cash retainer payment. Read SEC document
July 01, 2024 Filed Jul 4, 2024 00:07 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	114	$0.00	$0.00	Disclosure SEC source: 0001127602-24-020150 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,870 F1 · kind: Stock award in lieu of cash retainer payment. Read SEC document
May 15, 2024 Filed May 16, 2024 21:59 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	3,636	$0.00 Strike: $60.50	$0.00	Disclosure SEC source: 0001127602-24-015718 · form4.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,636 Underlying: Common Stock · 3,636 shares Expires 2034-05-15 Read SEC document
May 15, 2024 Filed May 16, 2024 21:59 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	5,600	$0.00	$0.00	Disclosure SEC source: 0001127602-24-015718 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,756 Read SEC document
January 02, 2024 Filed Jan 3, 2024 21:29 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	74	$84.12	$6,224.88	Disclosure SEC source: 0001127602-24-000441 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,156 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares issued at per share price of $84.12, representing the Issuer's closing stock price on January 2, 2024. Read SEC document
October 02, 2023 Filed Oct 3, 2023 20:13 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	224	$27.88	$6,245.12	Disclosure SEC source: 0001127602-23-025160 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,082 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $27.88, representing the Issuer's closing stock price on October 2, 2023. Read SEC document
July 07, 2023 Filed Jul 11, 2023 00:39 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	5,957	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-020553 · form4.xml · derivative · entry 4 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. F3 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document
July 07, 2023 Filed Jul 11, 2023 00:39 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,430	$29.88	$42,728.40	Disclosure SEC source: 0001127602-23-020553 · form4.xml · nonDerivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,356 Read SEC document
July 07, 2023 Filed Jul 11, 2023 00:39 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	5,957	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-020553 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document
July 03, 2023 Filed Jul 5, 2023 20:26 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	187	$33.36	$6,238.32	Disclosure SEC source: 0001127602-23-020071 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,858 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $33.36, representing the Issuer's closing stock price on July 3, 2023. Read SEC document
June 29, 2023 Filed Jun 30, 2023 20:38 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	5,985	$0.00	$0.00	Disclosure SEC source: 0001127602-23-019636 · form4.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,985 Underlying: Ordinary Shares · 5,985 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document
June 29, 2023 Filed Jun 30, 2023 20:38 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	12,732	$0.00 Strike: $31.33	$0.00	Disclosure SEC source: 0001127602-23-019636 · form4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,732 Underlying: Ordinary Shares · 12,732 shares Expires 2033-06-29 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document
May 10, 2023 Filed May 18, 2023 21:08 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $37.89	$0.00	Disclosure SEC source: 0001127602-23-016183 · form4.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-10 F2 · kind: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2023 and the last such installment vesting on 05/10/2024. Read SEC document
May 10, 2023 Filed May 18, 2023 21:08 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001127602-23-016183 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,671 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2024. Read SEC document
May 09, 2023 Filed May 10, 2023 20:34 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative	6,250	$0.00 Strike: $31.13	$0.00	Disclosure SEC source: 0001127602-23-015117 · form4.xml · derivative · entry 6 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,250 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2023. These options were scheduled to expire on May 15, 2023. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
May 09, 2023 Filed May 10, 2023 20:34 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $31.13	$0.00	Disclosure SEC source: 0001127602-23-015117 · form4.xml · derivative · entry 5 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 35,000 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2023. These options were scheduled to expire on May 15, 2023. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
May 09, 2023 Filed May 10, 2023 20:34 UTC	Alkermes plc. ALKS · Entity 2392	SaleOrdinary Shares	41,250	$31.24	$1,288,786.13	Disclosure SEC source: 0001127602-23-015117 · form4.xml · nonDerivative · entry 3 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,829 F1 · kind: This exercise and sale of options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2023. These options were scheduled to expire on May 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.23 to $31.33. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document
May 09, 2023 Filed May 10, 2023 20:34 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	6,250	$31.13	$194,562.50	Disclosure SEC source: 0001127602-23-015117 · form4.xml · nonDerivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2023. These options were scheduled to expire on May 15, 2023. Read SEC document
May 09, 2023 Filed May 10, 2023 20:34 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	35,000	$31.13	$1,089,550.00	Disclosure SEC source: 0001127602-23-015117 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale of options was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2023. These options were scheduled to expire on May 15, 2023. Read SEC document
April 27, 2023 Filed Apr 27, 2023 18:09 UTC	Provention Bio, Inc. PRVB · Entity 12101	Disposition to issuerOption to Purchase Common Stock · Derivative	33,000	Not disclosed Strike: $4.52	Not disclosed	Disclosure SEC source: 0001493152-23-013921 · ownership.xml · derivative · entry 4 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,000 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document
April 27, 2023 Filed Apr 27, 2023 18:09 UTC	Provention Bio, Inc. PRVB · Entity 12101	Disposition to issuerOption to Purchase Common Stock · Derivative	23,000	Not disclosed Strike: $6.80	Not disclosed	Disclosure SEC source: 0001493152-23-013921 · ownership.xml · derivative · entry 3 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,000 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document
April 27, 2023 Filed Apr 27, 2023 18:09 UTC	Provention Bio, Inc. PRVB · Entity 12101	Disposition to issuerOption to Purchase Common Stock · Derivative	22,200	Not disclosed Strike: $12.62	Not disclosed	Disclosure SEC source: 0001493152-23-013921 · ownership.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,200 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document
April 27, 2023 Filed Apr 27, 2023 18:09 UTC	Provention Bio, Inc. PRVB · Entity 12101	Disposition to issuerOption to Purchase Common Stock · Derivative	128,981	Not disclosed Strike: $13.16	Not disclosed	Disclosure SEC source: 0001493152-23-013921 · ownership.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 128,981 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · price: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.exercise_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2 · derivative.expiration_date: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. Read SEC document
April 03, 2023 Filed Apr 5, 2023 20:02 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	149	$37.71	$5,618.79	Disclosure SEC source: 0001127602-23-012536 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,671 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $37.71, representing the closing stock price of the Issuer's common stock on April 3, 2023. Read SEC document
January 03, 2023 Filed Jan 4, 2023 23:42 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	126	$44.35	$5,588.10	Disclosure SEC source: 0001127602-23-000718 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,522 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $44.35, representing the Issuer's closing stock price on January 3, 2023. Read SEC document
October 03, 2022 Filed Oct 5, 2022 20:25 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	110	$51.11	$5,622.10	Disclosure SEC source: 0001127602-22-023702 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,396 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $51.11, representing the closing stock price of the Issuer's common stock on October 3, 2022. Read SEC document
July 07, 2022 Filed Jul 8, 2022 20:26 UTC	Alkermes plc. ALKS · Entity 2392	GrantNon Qualified Stock Option (Right to Buy) · Derivative	11,554	$0.00 Strike: $31.48	$0.00	Disclosure SEC source: 0001127602-22-019136 · form4.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,554 Underlying: Ordinary Shares · 11,554 shares Expires 2032-07-07 F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 7/7/2023. Read SEC document
July 07, 2022 Filed Jul 8, 2022 20:26 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	5,957	$0.00	$0.00	Disclosure SEC source: 0001127602-22-019136 · form4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,957 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023. Read SEC document
July 01, 2022 Filed Jul 12, 2022 20:41 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	137	$41.00	$5,617.00	Disclosure SEC source: 0001127602-22-019243 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,286 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $41.00, representing the closing stock price of the Issuer's common stock on July 1, 2022. Read SEC document
June 14, 2022 Filed Jun 16, 2022 21:00 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	7,585	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-017641 · form4.xml · derivative · entry 4 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,585 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. F3 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document
June 14, 2022 Filed Jun 16, 2022 21:00 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	695	$27.19	$18,897.05	Disclosure SEC source: 0001127602-22-017641 · form4.xml · nonDerivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,829 Read SEC document
June 14, 2022 Filed Jun 16, 2022 21:00 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	7,585	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-017641 · form4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document
May 17, 2022 Filed May 18, 2022 18:08 UTC	Provention Bio, Inc. PRVB · Entity 12101	GrantStock Option (right to buy) · Derivative	33,000	$0.00 Strike: $4.52	$0.00	Disclosure SEC source: 0001493152-22-014373 · ownership.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock, par value $0.0001 · 33,000 shares Expires 2032-05-17 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: The options will vest in full and become exercisable upon the earlier to occur of (a) the business day before the Issuer's next annual meeting of stockholders and (b) May 17, 2023. Read SEC document
May 10, 2022 Filed May 11, 2022 22:07 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantNon-Qualified Stock Option (right to buy) · Derivative	10,000	$0.00 Strike: $37.89	$0.00	Disclosure SEC source: 0001061983-22-000123 · edgardoc.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-05-10 F2 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2022 and the last such installment vesting on 05/10/2023. Read SEC document
May 10, 2022 Filed May 11, 2022 22:07 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001061983-22-000123 · edgardoc.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,149 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2023. Read SEC document
April 01, 2022 Filed Apr 1, 2022 23:17 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	146	$38.38	$5,603.48	Disclosure SEC source: 0001061983-22-000091 · edgardoc.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,149 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares issued at per share price of $38.38, representing the Issuer's closing stock price on April 1, 2022. Read SEC document
January 03, 2022 Filed Jan 4, 2022 21:48 UTC	CYTOKINETICS INC CYTK · Entity 3528	GrantCommon Stock	122	$46.00	$5,612.00	Disclosure SEC source: 0001061983-22-000014 · edgardoc.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,003 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $46.00, representing the Issuer's closing stock price on January 3, 2022. F2 · balance_after: Amount includes 1,003 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document
December 02, 2021 Filed Dec 4, 2021 02:29 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	5,578	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-21-030305 · form4.xml · derivative · entry 4 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. F3 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document
December 02, 2021 Filed Dec 4, 2021 02:29 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,339	$22.11	$29,605.29	Disclosure SEC source: 0001127602-21-030305 · form4.xml · nonDerivative · entry 2 Wysenski Nancy · CIK 0001294596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,939 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.